Low flow and minimal flow anaesthesia with sevoflurane;Low flow- und minimal flow-anasthesie mit sevofluran

Anaesthesist

Volumn 47, Issue SUPPL. 1, 1998, Pages

  Baum, J ^a   Stanke, H G ^b  

^a Krankenhaus St Elisabeth Stift   (Germany)

^b NONE

Author keywords

Compound A; Low flow anaesthesia; Minimal flow anaesthesia; Sevoflurane; Soda lime

Indexed keywords

CALCIUM OXIDE; CARBON DIOXIDE; SEVOFLURANE; SODIUM CARBONATE;

BREATHING APPARATUS; DRUG ABSORPTION; DRUG DEGRADATION; GAS FLOW; HUMAN; INHALATION ANESTHESIA; PATIENT MONITORING; REVIEW;

ANESTHESIA, INHALATION; ANESTHETICS, INHALATION; HUMANS; METHYL ETHERS;

EID: 0032407557     PISSN: 00032417     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00002503     Document Type: Review

References (35)

1. Baum J (1994) Niedrigflußnarkosen. Anaesthesist 43:194-210
2. Baum J, Strauß JM (1995) Kohlenmonoxidbildung am Atemkalk. Anästh Intensivmed 36:237-240
3. Baum JA, Aitkenhead AR (1995) Low-flow anaesthesia. Anaesthesia [Suppl] 50:37-44
4. Baum J, Berghoff M, Stanke HG, Petermeyer M, Kalff G (1997) Niedrigflußnarkosen mit Desfluran. Anaesthesist 46:287-293
5. Baum J, Sitte T, Strauß JM, Forst H, Zimmermann M, Kugler B (1998) Die Reaktion von Sevofluran mit trockenem Atemkalk - Überlegungen zu einem aktuellen Zwischenfall. Anästh Intensivmed 39:11-16
6. Bito H, Ikeda K (1996) Renal and hepatic function in surgical patients after low-flow sevoflurane or isoflurane anesthesia. Anesth Analg 82:173-176
7. Bito H, Ikeuchi Y, Ikeda K (1997) Effects of low-flow sevoflurane anesthesia on renal function. Comparison with high-flow sevoflurane and low-flow isoflurane anesthesia. Anesthesiology 86:1231-1237
8. CEN - Comité Européen de Normalisation (ed) (1996) Anaesthetic Workstations and their modules - Particular requirements. prEN 740, Brüssel
9. Conzen P, Nuscheler M (1996) Neue Inhalationsanästhetika. Anaesthesist 45:674-693
10. Cunnigham DD, Huang S, Webster J, Mayoral J, Grabenkort RW (1996) Sevoflurane degradation to compound A in anaesthesia breathing systems. Br J Anaesth 77:537-543
11. Deutsches Institut für Normung (1991) Deutsche Norm Inhalationsnarkosegeräte. Entwurf DIN 13 252 A1. Beuth, Berlin
12. Eger II EI (1994) New inhaled anesthetics. Anesthesiology 80:906-922
13. Eger ll EI, Koblin DD, Bowland T, Ionescu P, Laster MJ, Fang Z, Gong D, Sonner J, Weiskopf RB (1997) Nephrotoxicity of sevoflurane versus desflurane anesthesia in volunteers. Anesth Analg 84:160-168
14. Fang ZX, Eger II EI (1995) Factors affecting the concentration of compound A resulting from degradation of sevoflurane by soda lime and Baralyme® in a standard anesthetic circuit. Anesth Analg 81:564-568
15. Fang ZX, Eger II EI, Laster MJ, Chortkoff BS, Kandel L, Ionescu P (1995) Carbon monoxide production from degradation of desflurane, enflurane isoflurane, halothane and sevoflurane by soda lime and baralyme. Anesth Anlag 80:1187-1193
16. Fang ZX, Kandel L, Laster MJ, Ionescu P, Eger II EI (1996) Factors affecting production of compound A from the interaction of sevoflurane with Baralyme® and soda lime. Anesth Analg 82:775-781
17. Förster H, Dudziak R (1997) Über die Ursachen der Reaktion von trockenem Atemkalk und halogenierten Inhaltionsanästhetika. Anaesthesist 46:1071-1075
18. Foldes FF, Ceravolo AJ, Carpenter SL (1952) The administration of nitrous oxide - oxigen anesthesia in closed systems. Ann Surg 136:978-981
19. Iyer RA, Anders MW (1996) Cysteine conjugate β-lyase-dependent biotransformation of the cysteine s-conjugate of the sevoflurane degradation product compound A in human, nonhuman primate, and rat kidney cytosol and mitochondria. Anesthesiology 85:1454-1461
20. Jahnsohn GP, Dudziak R (1997) Interaktionen von trockenem Atemkalk mit Enfluran und Sevofluran. Klinischer Bericht über zwei ungewöhnliche Anästhesieverläufe. Anaesthesist 46:1050-1053
21. Jin L, Baillie TA, Davis MR, Kharasch ED (1995) Nephrotoxicity of sevoflurane compound A in rats: evidence for glutathione and cysteine conjugate formation and the role of renal cysteine conjugate β-lyase. Biochem Biophys Res Comm 210:498-506
22. Kharash ED, Thorning D, Garton K, Hankins DC, Kilty GC (1997) Role of renal cysteine conjugate beta-lyase in the mechanism of compound A nephrotoxicity in rats. Anesthesiology 86:160-171
23. Kharash ED, Frink EJ, Zager R, Bowdle TA, Artru A, Nogami WM (1997) Assessment of low-flow sevoflurane and isoflurane effects on renal function using sensitive markers of tubular toxicity. Anesthesiology 86:1238-1253
24. Martin JL, Laster MJ, Kandel L, Kerschmann RL, Reed GF, Eger II EI (1996) Metabolism of compound A by renal cysteine-S-conjugate beta-lyase is not the mechanism of compound A-induced renal injury in the rat. Anesth Anal 82:770-774
25. Mazze RI, Jamison RL (1997) Low-flow (1 l/min) sevoflurane - Is it safe? Anesthesiology 86:1225-1227
26. Schmucker P (1995) Qualitätssicherung in der Anästhesiologie. Anästh Intensivmed 36:250-254
27. Sharp HJ, Trudell JR, Cohen EN (1979) Volatile metabolites and decomposition products of halothane in man. Anesthesiology 50:2-8
28. Smith I, Nathanson M, White PF (1996) Sevoflurane - a long-awaited volatile anaesthetic. Br J Anaesth 76:435-445
29. Strauß JM, Baum J, Sümpelmann R, Krohn S, Callies A (1996) Zersetzung von Halothan, Enfluran und Isofluran an trockenem Atemkalk zu Kohlenmonoxid. Anaesthesist 45:798-801
30. Strum DR, Eger II EI (1994) The degradation, absorption, and solubility of volatile anesthetics in soda lime depend on water content. Anesth Analg 78:340-348
31. Stuttmann R, Knüttgen D, Müller MR, Winkert AT, Doehn M (1993) Halothanabsorption durch trockenen Atemkalk. Anaesthesist 42:157-161
32. Virtue RW (1974) Minimal flow nitrous oxide anesthesia. Anesthesiology 40:196-198
33. Wissing H, Kuhn I, Dudziak R (1997) Zur Temperaturentwicklung von Inhalationsanästhetika auf trockenem Atemkalk. Anaesthesist 46:1064-1070
34. Woehlk HJ, Dunning M, Conolly MA (1997) Reduction in the incidence of carbon monoxide exposures in humans undergoing general anaesthesia. Anesthesiology 87:228-234
35. 2-Absorber - Zur Problematik des trockenen Atemkalks. Anästh Intensivmed 39:7-10